REMEGEN CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.45 HKD | -0.20% |
|
-2.12% | -32.04% |
| May. 28 | Grange Resources Appoints CEO | MT |
| Apr. 26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 1.65B 228M 1.78B | Sales 2025 * | 2.52B 347M 2.71B | Capitalization | 20.71B 2.86B 22.33B |
|---|---|---|---|---|---|
| Net income 2024 * | -1.28B -177M -1.38B | Net income 2025 * | -756M -104M -815M | EV / Sales 2024 * | 13.5 x |
| Net Debt 2024 * | 1.52B 210M 1.64B | Net Debt 2025 * | 1.83B 253M 1.97B | EV / Sales 2025 * | 8.96 x |
| P/E ratio 2024 * |
-9.98
x | P/E ratio 2025 * |
-17.1
x | Employees | 3,615 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.32% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.20% | ||
| 1 week | -2.12% | ||
| Current month | +0.39% | ||
| 1 month | -14.60% | ||
| 3 months | +17.01% | ||
| 6 months | -40.26% | ||
| Current year | -32.04% |
1 week
23.55
27.45
1 month
22.8033.20
Current year
14.9637.45
1 year
14.9650.30
3 years
14.96145.50
5 years
14.96149.80
10 years
14.96149.80
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Min Fang
CEO | Chief Executive Officer | 62 | 08-07-03 |
Shao Jing Tong
DFI | Director of Finance/CFO | 53 | 23-09-27 |
Ruyi He
CTO | Chief Tech/Sci/R&D Officer | 63 | 20-05-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xian Jing Hao
BRD | Director/Board Member | 59 | 20-05-10 |
Yun Jin Chen
BRD | Director/Board Member | 39 | 22-05-04 |
Jian Min Fang
CEO | Chief Executive Officer | 62 | 08-07-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 4 M€ | -27.92% | ||
| 0.12% | 2 M€ | -14.14% | ||
| 0.00% | 7 M€ | +6.05% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 25.45 | -0.20% | 518 000 |
| 24-06-05 | 25.5 | -0.58% | 1,503,674 |
| 24-06-04 | 25.65 | +7.55% | 2,227,000 |
| 24-06-03 | 23.85 | -5.92% | 1,788,444 |
| 24-05-31 | 25.35 | +0.80% | 2,630,500 |
Delayed Quote Hong Kong S.E., June 06, 2024 at 04:08 am EDT
More quotes
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
23.61
CNY
Average target price
38.75
CNY
Spread / Average Target
+64.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.04% | 2.93B | |
| +18.36% | 125B | |
| +13.90% | 109B | |
| -2.96% | 24.74B | |
| +2.71% | 22.67B | |
| -9.95% | 18.14B | |
| -41.48% | 16.67B | |
| -11.66% | 16.64B | |
| -0.07% | 13.45B | |
| +22.25% | 11.32B |
- Stock Market
- Equities
- 9995 Stock
